ArticleFrontiers in pharmacology2026
Incidence and characteristics of eravacycline-associated increase in serum bilirubin levels: a retrospective study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world safety profile of eravacycline compared with tigecycline, minocycline, and meropenem: a comparative pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare the effects of eravacycline and tigecycline on serum bilirubin levels and investigate the incidence and clinical characteristics of total bilirubin increase associated with eravacycline. Methods: We conducted a retrospective study in critically ill patients receiving eravacycline or tigecycline between November 2023 and May 2024 to evaluate serum bilirubin levels. Causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale. A multivariable logistic regression was conducted to identify the risk factors for an increase in total bilirubin, and Kaplan-Meier curves were used to depict the time to an increase in total bilirubin. Results: A total of 48 patients were evaluated in this study. Compared to tigecycline, eravacycline was associated with elevated serum total bilirubin and direct bilirubin. Following the definition of an increase in total bilirubin levels as ≥42 μmol/L, 15 patients were rated as possibly or probably having drug-associated increase in total bilirubin. The incidence of an increase in total bilirubin was 61.5% in the eravacycline group and only 20.0% in the tigecycline group. Administration of eravacycline was identified as an independent risk factor for an increase in total bilirubin. In addition, patients receiving eravacycline tended to experience an increase in total bilirubin significantly earlier, and the change in direct bilirubin levels was significantly greater than that in indirect bilirubin in these patients. Conclusion: Eravacycline has been identified as an independent risk factor for the increase in total bilirubin. Monitoring serum bilirubin levels should be considered in patients receiving eravacycline, particularly in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.